Literature DB >> 8944332

Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.

C Bouchet-Bernet1, F Spyratos, C Andrieu, S Deytieux, V Bécette, J Oglobine.   

Abstract

The levels of uPA, its inhibitors PAI-1 and PAI-2, and the uPA receptor (uPAR) have prognostic value in breast cancer. However, different extraction methods and assays kits are used in different laboratories and may directly influence the levels observed. To define a buffer suitable for both PAI-2 and uPAR extraction from breast cancer tissue compatible with hormone receptors and other cytosolic prognosticator assays, we compared PAI-2 and uPAR values obtained by immunoenzymatic assays (American Diagnostica, Greenwhich, USA) in several extraction conditions: 1) cytosol obtained with the standard hormone receptor buffer; 2) solubilized pellets obtained by Triton X100 extraction of the pelleted membranes obtained with standard hormone receptor buffer; 3) cytosol obtained by direct extraction in the buffer (containing Triton X100) recommended by the manufacturer, after 2 hours or 12 hours of incubation. Cytosol extracts prepared using the standard procedure recommended for hormone receptors gave the highest PAI-2 values. The highest uPAR values were obtained in the subsequent detergent extraction of the pelleted membranes. PAI-2 levels obtained with the kit manufacturer's method after 12 hours of incubation were lower than those obtained after 2 hours of incubation, whereas uPAR levels were similar. We conclude that the most suitable extraction protocol employs standard hormone receptor extraction buffer to obtain a supernatant cytosol fraction for PAI-2 assay, and subsequent detergent extraction of the pelleted membranes to obtain an extract suitable for uPAR.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944332     DOI: 10.1007/bf01807159

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

Authors:  W Hollas; F Blasi; D Boyd
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

2.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

3.  Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation.

Authors:  K J Wiechelman; R D Braun; J D Fitzpatrick
Journal:  Anal Biochem       Date:  1988-11-15       Impact factor: 3.365

4.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

5.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Authors:  J A Foekens; M Schmitt; W L van Putten; H A Peters; M D Kramer; F Jänicke; J G Klijn
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

6.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.

Authors:  E Bianchi; R L Cohen; A T Thor; R F Todd; I F Mizukami; D A Lawrence; B M Ljung; M A Shuman; H S Smith
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

7.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

8.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

Authors:  J A Foekens; F Buessecker; H A Peters; U Krainick; W L van Putten; M P Look; J G Klijn; M D Kramer
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

9.  Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.

Authors:  S Romain; F Spyratos; C Lainé-Bidron; C Bouchet; O Guirou; P M Martin; J Oglobine; H Magdelénat
Journal:  Eur J Clin Chem Clin Biochem       Date:  1995-09

10.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Authors:  C Bouchet; F Spyratos; P M Martin; K Hacène; A Gentile; J Oglobine
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  3 in total

1.  Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Authors:  Susanne Fuessel; Kati Erdmann; Helge Taubert; Andrea Lohse-Fischer; Stefan Zastrow; Matthias Meinhardt; Karen Bluemke; Lorenz Hofbauer; Paolo Fornara; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Manfred P Wirth; Matthias Kotzsch
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

2.  CD38 Defines a Subset of B Cells in Rainbow Trout Kidney With High IgM Secreting Capacities.

Authors:  Diana Martín; Pedro Perdiguero; Esther Morel; Irene Soleto; J German Herranz-Jusdado; Luis A Ramón; Beatriz Abós; Tiehui Wang; Patricia Díaz-Rosales; Carolina Tafalla
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

3.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Authors:  C Bouchet; F Spyratos; K Hacène; L Durcos; V Bécette; J Oglobine
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.